On October 7, CANSINOBIO fell 5.17% intraday, trading at HK$38.04 with turnover of HK$14.82 million. The pullback followed a strong rally spurred by expectations around the European Society for Medical Oncology conference, with short-term profit-taking emerging as the near-term catalyst fades.

Recent gains were fueled by Moderna's announcement that three abstracts on its individualized mRNA neoantigen therapy would be presented at the upcoming meeting, lifting mRNA-related vaccine names broadly. CANSINOBIO has been developing an mRNA platform and previously signed a strategic cooperation agreement with Deps Bio to co-develop personalized therapeutic tumor vaccines, with CANSINOBIO providing delivery and formulation capabilities. The Company has also laid out research programs in glioblastoma, rhabdomyosarcoma and cervical cancer, though these remain at an early stage.

CANSINOBIO is a clinical-stage Chinese vaccine company, with products primarily covering meningitis, DTP and pneumonia, and its business spans innovative vaccine research, development, production and commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)